Pharmaceutica Analytica Acta

Hyaluronic acid modified z pH-sensitive nanovector for targeted intracellular delivery of cytotoxic agent

4^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 24-26, 2014 Hilton San Antonio Airport, San Antonio, USA

Shivani Rai Paliwal

Accepted Abstracts: Pharmaceut Anal Acta

Abstract:

The aim of present study was the development of hyaluronic acid (HA)-targeted pH-sensitive liposomes (SL-pH-HA) for intracellular delivery of doxorubicin (DOX) in the cancer cell that express CD44. The in vitro release studies demonstrated that the release of DOX from SL-pH-HA was pH-dependent, i.e., faster at mildly acidic pH ~5, compared to physiological pH ~7.4. SL-pH-HA was evaluated for cytotoxicity potential on MCF-7 cells. The quantitative uptake study by flow cytometry revealed higher localization of targeted liposomes in the receptor positive cells, which was further confirmed by fluorescent microscopy. The in vivo antitumor activity in tumor bearing mice was also confirmed the efficacy of HA targeted pH-sensitive liposomes. The major side-effect of DOX i.e., cardiotoxicity was also estimated by measuring serum enzyme level. Thus, HA targeted pH-sensitive liposomes were significantly more potent than the non-targeted liposomes in cells expressing high levels of CD44, which suggests that they may be a useful targeted drug carrier to treat CD44-expressing breast tumors.